Seminars in Radiation Oncology
Volume 18, Issue 2 , Pages 136-148 , April 2008

Targeted Molecular Imaging in Oncology: Focus on Radiation Therapy

  • Sridhar Nimmagadda, PhD

      Affiliations

    • Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins Medical Institutions, Baltimore, MD.
    • ,
  • Eric C. Ford, PhD

      Affiliations

    • Department of Radiation Oncology and Molecular Radiation Sciences, The Sidney Kimmel Comprehensive Cancer at Johns Hopkins, Baltimore, MD.
    • ,
  • John W. Wong, PhD

      Affiliations

    • Department of Radiation Oncology and Molecular Radiation Sciences, The Sidney Kimmel Comprehensive Cancer at Johns Hopkins, Baltimore, MD.
    • ,
  • Martin G. Pomper, MD, PhD

      Affiliations

    • Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins Medical Institutions, Baltimore, MD.
    • Corresponding Author InformationAddress reprint requests to Martin G. Pomper, MD, PhD, Johns Hopkins Medical Institutions, 1550 Orleans Street, 492 CRB II, Baltimore, MD 21231.

References 

  1. Olive KP, Tuveson DA. The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin Cancer Res. 2006;1512:5277–5287
  2. Sharpless NE, Depinho RA. The mighty mouse: Genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov. 2006;5:741–754
  3. Singh M, Johnson L. Using genetically engineered mouse models of cancer to aid drug development: An industry perspective. Clin Cancer Res. 2006;1512:5312–5328
  4. Van Dyke T, Jacks T. Cancer modeling in the modern era: progress and challenges. Cell. 2002;25108:135–144
  5. Pomper MG. Molecular imaging: An overview. Acad Radiol. 2001;8:1141–1153
  6. Pomper MG. Translational molecular imaging for cancer. Cancer Imaging. 2005;5 Spec No A:S16–S26
  7. Pomper MG, Phillips E, Fan H, et al. Synthesis and biodistribution of radiolabeled {alpha}7 nicotinic acetylcholine receptor ligands. J Nucl Med. 2005;46:326–334
  8. Massoud TF, Gambhir SS. Molecular imaging in living subjects: Seeing fundamental biological processes in a new light. Genes Dev. 2003;117:545–580
  9. Gelovani Tjuvajev J, Blasberg RG. In vivo imaging of molecular-genetic targets for cancer therapy. Cancer Cell. 2003;3:327–332
  10. Warburg O. On the origin of cancer cells. Science. 1956;24123:309–314
  11. Ak I, Stokkel MP, Pauwels EK. Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose in oncology (Part II. The clinical value in detecting and staging primary tumours). J Cancer Res Clin Oncol. 2000;126:560–574
  12. Pauwels EK, Sturm EJ, Bombardieri E, et al. Positron-emission tomography with [18F]fluorodeoxyglucose (Part I. Biochemical uptake mechanism and its implication for clinical studies). J Cancer Res Clin Oncol. 2000;126:549–559
  13. Gambhir SS, Czernin J, Schwimmer J, et al. A tabulated summary of the FDG PET literature. J Nucl Med. 2001;42(suppl):1S–93S
  14. van Baardwijk A, Baumert BG, Bosmans G, et al. The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning. Cancer Treat Rev. 2006;32:245–260
  15. Bradley J, Thorstad WL, Mutic S, et al. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004;159:78–86
  16. Caldwell CB, Mah K, Ung YC, et al. Observer variation in contouring gross tumor volume in patients with poorly defined non-small-cell lung tumors on CT: The impact of 18FDG-hybrid PET fusion. Int J Radiat Oncol Biol Phys. 2001;1551:923–931
  17. Gondi V, Bradley K, Mehta M, et al. Impact of hybrid fluorodeoxyglucose positron-emission tomography/computed tomography on radiotherapy planning in esophageal and non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2007;167:187–195
  18. Andrade RS, Heron DE, Degirmenci B, et al. Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys. 2006;165:1315–1322
  19. Gregoire V, Bol A, Geets X, Lee J. Is PET-based treatment planning the new standard in modern radiotherapy? (The head and neck paradigm). Semin Radiat Oncol. 2006;16:232–238
  20. Tralins KS, Douglas JG, Stelzer KJ, et al. Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: Prognostic information and possible role in definition of target volumes in radiation dose escalation. J Nucl Med. 2002;43:1667–1673
  21. Sakurai H, Suzuki Y, Nonaka T, et al. FDG-PET in the detection of recurrence of uterine cervical carcinoma following radiation therapy—Tumor volume and FDG uptake value. Gynecol Oncol. 2006;100:601–607
  22. Cascini GL, Avallone A, Delrio P, et al. 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. J Nucl Med. 2006;47:1241–1248
  23. Westerterp M, van Westreenen HL, Reitsma JB, et al. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy—Systematic review. Radiology. 2005;236:841–851
  24. Kasamon YL, Jones RJ, Wahl RL. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. J Nucl Med. 2007;48(suppl 1):19S–27S
  25. Erdi YE, Mawlawi O, Larson SM, et al. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer. 1997;80(suppl):2505–2509
  26. Ford EC, Kinahan PE, Hanlon L, et al. Tumor delineation using PET in head and neck cancers: Threshold contouring and lesion volumes. Med Phys. 2006;33:4280–4288
  27. Allal AS, Dulguerov P, Allaoua M, et al. Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol. 2002;120:1398–1404
  28. Allal AS, Slosman DO, Kebdani T, et al. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys. 2004;159:1295–1300
  29. Brun E, Kjellen E, Tennvall J, et al. FDG PET studies during treatment: Prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck. 2002;24:127–135
  30. Cerfolio RJ, Ojha B, Mukherjee S, et al. Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma. J Thorac Cardiovasc Surg. 2003;125:938–944
  31. Mac Manus MP, Hicks RJ, Matthews JP, et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 2003;121:1285–1292
  32. Rege S, Safa AA, Chaiken L, et al. Positron emission tomography: An independent indicator of radiocurability in head and neck carcinomas. Am J Clin Oncol. 2000;23:164–169
  33. Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol. 2003;1521:2651–2657
  34. Hautzel H, Muller-Gartner HW. Early changes in fluorine-18-FDG uptake during radiotherapy. J Nucl Med. 1997;38:1384–1386
  35. Yao M, Graham MM, Smith RB, et al. Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: A preliminary report. Int J Radiat Oncol Biol Phys. 2004;160:1410–1418
  36. Erdi YE, Macapinlac H, Rosenzweig KE, et al. Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med. 2000;27:861–866
  37. Charnley N, West CM, Barnett CM, et al. Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy. Int J Radiat Oncol Biol Phys. 2006;166:331–338
  38. Rozental JM, Levine RL, Mehta MP, et al. Early changes in tumor metabolism after treatment: The effects of stereotactic radiotherapy. Int J Radiat Oncol Biol Phys. 1991;20:1053–1060
  39. Spence AM, Muzi M, Graham MM, et al. 2-[(18)F]Fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy: Correlation with outcome. Clin Cancer Res. 2002;8:971–979
  40. Kubota R, Yamada S, Kubota K, et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: High accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972–1980
  41. Arslan N, Miller TR, Dehdashti F, et al. Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography in patients with esophageal cancer. Mol Imaging Biol. 2002;4:301–310
  42. Pugachev A, Ruan S, Carlin S, et al. Dependence of FDG uptake on tumor microenvironment. Int J Radiat Oncol Biol Phys. 2005;162:545–553
  43. Ford E, Lavely W, Frassica D, et al. Comparison of FDG-PET/CT and CT for delineation of lumpectomy cavity for partial breast irradiation, submitted. Int J Radiat Oncol Biol Phys. 2007;(in press)
  44. Busch H, Davis JR, Honig GR, et al. The uptake of a variety of amino acids into nuclear proteins of tumors and other tissues. Cancer Res. 1959;19:1030–1039
  45. Isselbacher KJ. Sugar and amino acid transport by cells in culture—Differences between normal and malignant cells. N Engl J Med. 1972;27286:929–933
  46. Laverman P, Boerman OC, Corstens FH, et al. Fluorinated amino acids for tumour imaging with positron emission tomography. Eur J Nucl Med Mol Imaging. 2002;29:681–690
  47. Jager PL, Vaalburg W, Pruim J, et al. Radiolabeled amino acids: Basic aspects and clinical applications in oncology. J Nucl Med. 2001;42:432–445
  48. Kuwert T, Morgenroth C, Woesler B, et al. Uptake of iodine-123-alpha-methyl tyrosine by gliomas and non-neoplastic brain lesions. Eur J Nucl Med. 1996;23:1345–1353
  49. Ogawa T, Shishido F, Kanno I, et al. Cerebral glioma: Evaluation with methionine PET. Radiology. 1993;186:45–53
  50. Yoshimoto M, Waki A, Obata A, et al. Radiolabeled choline as a proliferation marker: Comparison with radiolabeled acetate. Nucl Med Biol. 2004;31:859–865
  51. Mankoff DA, Shields AF, Krohn KA. PET imaging of cellular proliferation. Radiol Clin North Am. 2005;43:153–167
  52. Kenny LM, Aboagye EO, Price PM. Positron emission tomography imaging of cell proliferation in oncology. Clin Oncol (R Coll Radiol). 2004;16:176–185
  53. Shields AF, Coonrod DV, Quackenbush RC, et al. Cellular sources of thymidine nucleotides: Studies for PET. J Nucl Med. 1987;28:1435–1440
  54. Quackenbush RC, Shields AF. Local re-utilization of thymidine in normal mouse tissues as measured with iododeoxyuridine. Cell Tissue Kinet. 1988;21:381–387
  55. Shields AF, Lim K, Grierson J, et al. Utilization of labeled thymidine in DNA synthesis: Studies for PET. J Nucl Med. 1990;31:337–342
  56. Shields AF, Graham MM, Kozawa SM, et al. Contribution of labeled carbon dioxide to PET imaging of carbon-11-labeled compounds. J Nucl Med. 1992;33:581–584
  57. Mankoff DA, Shields AF, Graham MM, et al. A graphical analysis method to estimate blood-to-tissue transfer constants for tracers with labeled metabolites. J Nucl Med. 1996;37:2049–2057
  58. Shields AF, Mankoff D, Graham MM, et al. Analysis of 2-carbon-11-thymidine blood metabolites in PET imaging. J Nucl Med. 1996;37:290–296
  59. Mankoff DA, Shields AF, Graham MM, et al. Kinetic analysis of 2-[carbon-11]thymidine PET imaging studies: Compartmental model and mathematical analysis. J Nucl Med. 1998;39:1043–1055
  60. Sherley JL, Kelly TJ. Human cytosolic thymidine kinase (Purification and physical characterization of the enzyme from HeLa cells). J Biol Chem. 1988;5263:375–382
  61. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334–1336
  62. Visvikis D, Francis D, Mulligan R, et al. Comparison of methodologies for the in vivo assessment of (18)FLT utilisation in colorectal cancer. Eur J Nucl Med Mol Imaging. 2003;31:169–178
  63. Choi SJ, Kim JS, Kim JH, et al. [(18)F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging. 2005;32:653–659
  64. Buck AK, Halter G, Schirrmeister H, et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med. 2003;44:1426–1431
  65. Kenny L, Coombes RC, Vigushin DM, et al. Imaging early changes in proliferation at 1 week post chemotherapy: A pilot study in breast cancer patients with 3′-deoxy-3′-[(18)F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging. 2007;34:1139–1347
  66. Sugiyama M, Sakahara H, Sato K, et al. Evaluation of 3′-deoxy-3′-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. J Nucl Med. 2004;45:1754–1758
  67. Apisarnthanarax S, Alauddin MM, Mourtada F, et al. Early detection of chemoradioresponse in esophageal carcinoma by 3′-deoxy-3′-3H-fluorothymidine using preclinical tumor models. Clin Cancer Res. 2006;112:4590–4597
  68. Yang YJ, Ryu JS, Kim SY, et al. Use of 3′-deoxy-3′-[18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors. Eur J Nucl Med Mol Imaging. 2006;33:412–419
  69. Sun H, Sloan A, Mangner TJ, et al. Imaging DNA synthesis with [(18)F]FMAU and positron emission tomography in patients with cancer. Eur J Nucl Med Mol Imaging. 2005;32:15–22
  70. Nimmagadda S, Mangner TJ, Sun H, et al. Biodistribution and radiation dosimetry estimates of 1-(2′-deoxy-2′-18F-fluoro-1-{beta}-D-arabinofuranosyl)-5-bromouracil: PET imaging studies in dogs. J Nucl Med. 2005;46:1916–1922
  71. Glunde K, Jacobs MA, Bhujwalla ZM. Choline metabolism in cancer: Implications for diagnosis and therapy. Expert Rev Mol Diagn. 2006;6:821–829
  72. Zheng QH, Stone KL, Mock BH, et al. [11C]Choline as a potential PET marker for imaging of breast cancer athymic mice. Nucl Med Biol. 2002;29:803–807
  73. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med. 1998;39:990–995
  74. Hara T, Kosaka N, Shinoura N, et al. PET imaging of brain tumor with [methyl-11C]choline. J Nucl Med. 1997;38:842–847
  75. DeGrado TR, Baldwin SW, Wang S, et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med. 2001;42:1805–1814
  76. DeGrado TR, Coleman RE, Wang S, et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: Initial findings in prostate cancer. Cancer Res. 2001;161:110–117
  77. Hara T, Bansal A, Degrado TR. Choline transporter as a novel target for molecular imaging of cancer. Mol Imaging. 2006;5:498–509
  78. Breeuwsma AJ, Pruim J, Jongen MM, et al. In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer. Eur J Nucl Med Mol Imaging. 2005;32:668–673
  79. Al-Saeedi F, Welch AE, Smith TA. [methyl-3H]Choline incorporation into MCF7 tumour cells: Correlation with proliferation. Eur J Nucl Med Mol Imaging. 2005;32:660–667
  80. Pathak AP, Gimi B, Glunde K, et al. Molecular and functional imaging of cancer: Advances in MRI and MRS. Methods Enzymol. 2004;386:3–60
  81. Gillies RJ, Morse DL. In vivo magnetic resonance spectroscopy in cancer. Annu Rev Biomed Eng. 2005;7:287–326
  82. Glunde K, Ackerstaff E, Mori N, Jacobs MA, Bhujwalla ZM. Choline phospholipid metabolism in cancer: Consequences for molecular pharmaceutical interventions. Mol Pharm. 2006;3:496–506
  83. Lichy MP, Bachert P, Hamprecht F, et al. [Application of (1)H MR spectroscopic imaging in radiation oncology: Choline as a marker for determining the relative probability of tumor progression after radiation of glial brain tumors]. Rofo. 2006;178:627–633
  84. Zeng QS, Li CF, Liu H, et al. Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion-weighted imaging. Int J Radiat Oncol Biol Phys. 2007;168:151–158
  85. Chao KS, Bosch WR, Mutic S, et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2001;1549:1171–1182
  86. Popple RA, Ove R, Shen S. Tumor control probability for selective boosting of hypoxic subvolumes, including the effect of reoxygenation. Int J Radiat Oncol Biol Phys. 2002;154:921–927
  87. Bussink J, Kaanders JH, Rijken PF, et al. Changes in blood perfusion and hypoxia after irradiation of a human squamous cell carcinoma xenograft tumor line. Radiat Res. 2000;153:398–404
  88. Cowen RL, Williams KJ, Chinje EC, et al. Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: Reversing tumor radioresistance and effecting cure. Cancer Res. 2004;1564:1396–1402
  89. Greco O, Joiner MC, Doleh A, et al. Hypoxia- and radiation-activated Cre/loxP ‘molecular switch’ vectors for gene therapy of cancer. Gene Ther. 2006;13:206–215
  90. Lipnik K, Greco O, Scott S, et al. Hypoxia- and radiation-inducible, breast cell-specific targeting of retroviral vectors. Virology. 2006;25349:121–133
  91. Padhani AR, Krohn KA, Lewis JS, et al. Imaging oxygenation of human tumours. Eur Radiol. 2007;17:861–872
  92. Rajendran JG, Krohn KA. Imaging hypoxia and angiogenesis in tumors. Radiol Clin North Am. 2005;43:169–187
  93. Rajendran JG, Schwartz DL, O’Sullivan J, et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res. 2006;1512:5435–5441
  94. Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy (An international multi-center study). Radiother Oncol. 2005;77:18–24
  95. Dubois L, Landuyt W, Haustermans K, et al. Evaluation of hypoxia in an experimental rat tumour model by [(18)F]fluoromisonidazole PET and immunohistochemistry. Br J Cancer. 2004;2991:1947–1954
  96. Koh WJ, Bergman KS, Rasey JS, et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys. 1995;3033:391–398
  97. Rajendran JG, Mankoff DA, O’Sullivan F, et al. Hypoxia and glucose metabolism in malignant tumors: Evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res. 2004;110:2245–2252
  98. Rajendran JG, Wilson DC, Conrad EU, et al. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: Correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging. 2003;30:695–704
  99. Cook GJ, Houston S, Barrington SF, et al. Technetium-99m-labeled HL91 to identify tumor hypoxia: Correlation with fluorine-18-FDG. J Nucl Med. 1998;39:99–103
  100. Zhang X, Melo T, Ballinger JR, et al. Studies of 99mTc-BnAO (HL-91): A non-nitroaromatic compound for hypoxic cell detection. Int J Radiat Oncol Biol Phys. 1998;142:737–740
  101. Fujibayashi Y, Taniuchi H, Yonekura Y, et al. Copper-62-ATSM: A new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997;38:1155–1160
  102. Dehdashti F, Mintun MA, Lewis JS, et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging. 2003;30:844–850
  103. Dehdashti F, Grigsby PW, Mintun MA, et al. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: Relationship to therapeutic response—A preliminary report. Int J Radiat Oncol Biol Phys. 2003;155:1233–1238
  104. Matsumoto K, Szajek L, Krishna MC, et al. The influence of tumor oxygenation on hypoxia imaging in murine squamous cell carcinoma using [64Cu]Cu-ATSM or [18F]Fluoromisonidazole positron emission tomography. Int J Oncol. 2007;30:873–881
  105. Lewis J, Laforest R, Buettner T, et al. Copper-64-diacetyl-bis(N4-methylthiosemicarbazone): An agent for radiotherapy. Proc Natl Acad Sci U S A. 2001;98:1206–1211
  106. Obata A, Kasamatsu S, Lewis JS, et al. Basic characterization of 64Cu-ATSM as a radiotherapy agent. Nucl Med Biol. 2005;32:21–28
  107. Aft RL, Lewis JS, Zhang F, Kim J, et al. Enhancing targeted radiotherapy by copper(II)diacetyl-bis(N4-methylthiosemicarbazone) using 2-deoxy-D-glucose. Cancer Res. 2003;163:5496–5504
  108. Burgman P, O’Donoghue JA, Lewis JS, et al. Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM. Nucl Med Biol. 2005;32:623–630
  109. Zanzonico P, O’Donoghue J, Chapman JD, et al. Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning. Eur J Nucl Med Mol Imaging. 2004;31:117–128
  110. Beck R, Roper B, Carlsen JM, et al. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine. J Nucl Med. 2007;48:973–980
  111. Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer. 2005;5:231–237
  112. Meyn RE, Stephens LC, Milas L. Programmed cell death and radioresistance. Cancer Metastasis Rev. 1996;15:119–131
  113. Boersma HH, Kietselaer BL, Stolk LM, et al. Past, present, and future of annexin A5: From protein discovery to clinical applications. J Nucl Med. 2005;46:2035–2050
  114. Yagle KJ, Eary JF, Tait JF, et al. Evaluation of 18F-annexin V as a PET imaging agent in an animal model of apoptosis. J Nucl Med. 2005;46:658–666
  115. Blankenberg FG, Katsikis PD, Tait JF, et al. Imaging of apoptosis (programmed cell death) with 99mTc annexin V. J Nucl Med. 1999;40:184–191
  116. Keen HG, Dekker BA, Disley L, et al. Imaging apoptosis in vivo using 124I-annexin V and PET. Nucl Med Biol. 2005;32:395–402
  117. Belhocine T, Steinmetz N, Hustinx R, et al. Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res. 2002;8:2766–2774
  118. Haas RL, de Jong D, Valdes Olmos RA, et al. In vivo imaging of radiation-induced apoptosis in follicular lymphoma patients. Int J Radiat Oncol Biol Phys. 2004;159:782–787
  119. Petrovsky A, Schellenberger E, Josephson L, et al. Near-infrared fluorescent imaging of tumor apoptosis. Cancer Res. 2003;1563:1936–1942
  120. Ntziachristos V, Schellenberger EA, Ripoll J, et al. Visualization of antitumor treatment by means of fluorescence molecular tomography with an annexin V-Cy5.5 conjugate. Proc Natl Acad Sci U S A. 2004;101:12294–12299
  121. Davletov BA, Sudhof TC. A single C2 domain from synaptotagmin I is sufficient for high affinity Ca2+/phospholipid binding. J Biol Chem. 1993;15268:26386–26390
  122. Zhao M, Beauregard DA, Loizou L, et al. Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent. Nat Med. 2001;7:1241–1244
  123. Massie C, Mills IG. The developing role of receptors and adaptors. Nat Rev Cancer. 2006;6:403–409
  124. Srinivasan DM, Kapoor M, Kojima F, et al. Growth factor receptors: Implications in tumor biology. Curr Opin Investig Drugs. 2005;6:1246–1249
  125. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;26339:1609–1618
  126. Linden HM, Stekhova SA, Link JM, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol. 2006;2024:2793–2799
  127. Dehdashti F, Mortimer JE, Siegel BA, et al. Positron tomographic assessment of estrogen receptors in breast cancer: Comparison with FDG-PET and in vitro receptor assays. J Nucl Med. 1995;36:1766–1774
  128. Dehdashti F, Picus J, Michalski JM, et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging. 2005;32:344–350
  129. Iznaga-Escobar N, Torres LA, Morales A, et al. Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I (Biodistribution and dosimetry for radioimmunotherapy). J Nucl Med. 1998;39:15–23
  130. Ramos-Suzarte M, Rodriguez N, Oliva JP, et al. 99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin: Part III (Clinical trials safety and diagnostic efficacy). J Nucl Med. 1999;40:768–775
  131. Ke S, Wen X, Gurfinkel M, et al. Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. Cancer Res. 2003;1563:7870–7875
  132. Mishani E, Abourbeh G, Rozen Y, et al. Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: Potential PET bioprobes for molecular imaging of EGFR-positive tumors. Nucl Med Biol. 2004;31:469–476
  133. Pal A, Glekas A, Doubrovin M, et al. Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography. Mol Imaging Biol. 2006;8:262–277
  134. Wang JQ, Gao M, Miller KD, et al. Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase. Bioorg Med Chem Lett. 2006;116:4102–4106
  135. Hynes NE, Lane HA. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341–354
  136. Cooke T, Reeves J, Lanigan A, et al. HER2 as a prognostic and predictive marker for breast cancer. Ann Oncol. 2001;12(suppl 1):S23–S28
  137. Robinson MK, Doss M, Shaller C, et al. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res Feb. 2005;1565:1471–1478
  138. Perik PJ, Lub-De Hooge MN, Gietema JA, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol May. 2006;2024:2276–2282
  139. Krenning EP, Bakker WH, Kooij PP, et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: Metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med. 1992;33:652–658
  140. Anderson CJ, Dehdashti F, Cutler PD, et al. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med. 2001;42(2):213–221
  141. Henze M, Schuhmacher J, Hipp P, et al. PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. J Nucl Med. 2001;42(7):1053–1056
  142. Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-DOTA-Tyr3-Octreotide PET in neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508–518
  143. Moore A, Josephson L, Bhorade RM, et al. Human transferrin receptor gene as a marker gene for MR imaging. Radiology. 2001;221:244–250
  144. Artemov D, Mori N, Okollie B, et al. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med. 2003;49:403–408
  145. Artemov D, Mori N, Ravi R, et al. Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res. 2003;163:2723–2727
  146. Penuelas I, Haberkorn U, Yaghoubi S, et al. Gene therapy imaging in patients for oncological applications. Eur J Nucl Med Mol Imaging. 2005;32(suppl 2):S384–S403
  147. Niu G, Gaut AW, Ponto LL, et al. Multimodality noninvasive imaging of gene transfer using the human sodium iodide symporter. J Nucl Med. 2004;45:445–449
  148. Groot-Wassink T, Aboagye EO, Wang Y, et al. Quantitative imaging of Na/I symporter transgene expression using positron emission tomography in the living animal. Mol Ther. 2004;9:436–442
  149. Liang Q, Satyamurthy N, Barrio JR, et al. Noninvasive, quantitative imaging in living animals of a mutant dopamine D2 receptor reporter gene in which ligand binding is uncoupled from signal transduction. Gene Ther. 2001;8:1490–1498
  150. MacLaren DC, Gambhir SS, Satyamurthy N, et al. Repetitive, non-invasive imaging of the dopamine D2 receptor as a reporter gene in living animals. Gene Ther. 1999;6:785–791
  151. Tjuvajev JG, Stockhammer G, Desai R, et al. Imaging the expression of transfected genes in vivo. Cancer Res. 1995;1555:6126–6132
  152. Tjuvajev JG, Avril N, Oku T, et al. Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res. 1998;58:4333–4341
  153. Gambhir SS, Bauer E, Black ME, et al. A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc Natl Acad Sci U S A. 2000;97:2785–2790
  154. Yaghoubi SS, Wu L, Liang Q, et al. Direct correlation between positron emission tomographic images of two reporter genes delivered by two distinct adenoviral vectors. Gene Ther. 2001;8:1072–1080
  155. Qiao J, Doubrovin M, Sauter BV, et al. Tumor-specific transcriptional targeting of suicide gene therapy. Gene Ther. 2002;9:168–175
  156. Doubrovin M, Ponomarev V, Beresten T, et al. Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. Proc Natl Acad Sci U S A. 2001;98:9300–9305
  157. Bhaumik S, Walls Z, Puttaraju M, et al. Molecular imaging of gene expression in living subjects by spliceosome-mediated RNA trans-splicing. Proc Natl Acad Sci U S A. 2004;101:8693–8698
  158. Luker GD, Sharma V, Pica CM, et al. Molecular imaging of protein-protein interactions: Controlled expression of p53 and large T-antigen fusion proteins in vivo. Cancer Res. 2003;1563:1780–1788
  159. Shu CJ, Guo S, Kim YJ, et al. Visualization of a primary anti-tumor immune response by positron emission tomography. Proc Natl Acad Sci U S A. 2005;102:17412–17417
  160. Jacobs A, Voges J, Reszka R, et al. Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet. 2001;358:727–729
  161. Peñuelas I, Mazzolini G, Boan JF, et al. Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology. 2005;128:1787–1795
  162. Fu DX, Tanhehco YC, Chen J, et al. Virus-associated tumor imaging by induction of viral gene expression. Clin Cancer Res. 2007;113:1453–1458
  163. Moeller BJ, Richardson RA, Dewhirst MW. Hypoxia and radiotherapy: Opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev. 2007;26:241–248
  164. Greco O, Marples B, Dachs GU, et al. Novel chimeric gene promoters responsive to hypoxia and ionizing radiation. Gene Ther. 2002;9:1403–1411
  165. Cohen B, Dafni H, Meir G, et al. Ferritin as an endogenous MRI reporter for noninvasive imaging of gene expression in C6 glioma tumors. Neoplasia. 2005;7:109–117
  166. Genove G, DeMarco U, Xu H, et al. A new transgene reporter for in vivo magnetic resonance imaging. Nat Med. 2005;11:450–454
  167. Gilad AA, McMahon MT, Walczak P, et al. Artificial reporter gene providing MRI contrast based on proton exchange. Nat Biotechnol. 2007;25:217–219
  168. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell. 1994;2179:185–188
  169. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27–31
  170. Shaked Y, Kerbel RS. Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Res. 2007;167:7055–7058
  171. Folkman J. Angiogenesis: An organizing principle for drug discovery?. Nat Rev Drug Discov. 2007;6:273–286
  172. Leach MO, Brindle KM, Evelhoch JL, et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: Issues and recommendations. Br J Cancer. 2005;992:1599–1610
  173. Kiessling F, Greschus S, Lichy MP, et al. Volumetric computed tomography (VCT): A new technology for noninvasive, high-resolution monitoring of tumor angiogenesis. Nat Med. 2004;10:1133–1138
  174. Cai W, Rao J, Gambhir SS, et al. How molecular imaging is speeding up antiangiogenic drug development. Mol Cancer Ther. 2006;5:2624–2633
  175. Tabruyn SP, Griffioen AW. Molecular pathways of angiogenesis inhibition. Biochem Biophys Res Commun. 2007;30355:1–5
  176. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002;2:795–803
  177. Cai W, Chen K, Mohamedali KA, et al. PET of vascular endothelial growth factor receptor expression. J Nucl Med. 2006;47:2048–2056
  178. Blankenberg FG, Backer MV, Levashova Z, et al. In vivo tumor angiogenesis imaging with site-specific labeled (99m)Tc-HYNIC-VEGF. Eur J Nucl Med Mol Imaging. 2006;33:841–848
  179. Blankenberg FG, Mandl S, Cao YA, et al. Tumor imaging using a standardized radiolabeled adapter protein docked to vascular endothelial growth factor. J Nucl Med. 2004;45:1373–1380
  180. Cornelissen B, Oltenfreiter R, Kersemans V, et al. In vitro and in vivo evaluation of [123I]-VEGF165 as a potential tumor marker. Nucl Med Biol. 2005;32:431–436
  181. Jayson GC, Zweit J, Jackson A, et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: Implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst. 2002;294:1484–1493
  182. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2:91–100
  183. Stupack DG, Cheresh DA. Integrins and angiogenesis. Curr Top Dev Biol. 2004;64:207–238
  184. Liu S. Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging. Mol Pharm. 2006;3:472–487
  185. Beer AJ, Haubner R, Sarbia M, et al. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res. 2006;112:3942–3949
  186. Haubner R, Weber WA, Beer AJ, et al. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med. 2005;2:e70
  187. Winter PM, Caruthers SD, Kassner A, et al. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res. 2003;1563:5838–5843
  188. Sipkins DA, Cheresh DA, Kazemi MR, et al. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med. 1998;4:623–626
  189. Anderson SA, Rader RK, Westlin WF, et al. Magnetic resonance contrast enhancement of neovasculature with alpha(v)beta(3)-targeted nanoparticles. Magn Reson Med. 2000;44:433–439
  190. Chen X, Conti PS, Moats RA. In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts. Cancer Res. 2004;164:8009–8014
  191. Ellegala DB, Leong-Poi H, Carpenter JE, et al. Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3. Circulation. 2003;22108:336–341
  192. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006;25:9–34
  193. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: Innovations for the post-trial era. Nat Rev Cancer. 2002;2:657–672
  194. Van de Wiele C, Oltenfreiter R. Imaging probes targeting matrix metalloproteinases. Cancer Biother Radiopharm. 2006;21:409–417
  195. Choe YS, Lee KH. Targeted in vivo imaging of angiogenesis: Present status and perspectives. Curr Pharm Des. 2007;13:17–31
  196. Furumoto S, Takashima K, Kubota K, et al. Tumor detection using 18F-labeled matrix metalloproteinase-2 inhibitor. Nucl Med Biol. 2003;30:119–125
  197. Giersing BK, Rae MT, CarballidoBrea M, et al. Synthesis and characterization of 111In-DTPA-N-TIMP-2: A radiopharmaceutical for imaging matrix metalloproteinase expression. Bioconjug Chem. 2001;12:964–971
  198. Medina OP, Kairemo K, Valtanen H, et al. Radionuclide imaging of tumor xenografts in mice using a gelatinase-targeting peptide. Anticancer Res. 2005;25:33–42
  199. Bremer C, Tung CH, Weissleder R. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med. 2001;7:743–748
  200. Mahmood U, Weissleder R. Near-infrared optical imaging of proteases in cancer. Mol Cancer Ther. 2003;2:489–496
  201. Funovics M, Montet X, Reynolds F, et al. Nanoparticles for the optical imaging of tumor E-selectin. Neoplasia. 2005;7:904–911
  202. Yang DJ, Kim KD, Schechter NR, et al. Assessment of antiangiogenic effect using 99mTc-EC-endostatin. Cancer Biother Radiopharm. 2002;17:233–245
  203. Nyati MK, Morgan MA, Feng FY, et al. Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer. 2006;6:876–885
  204. Hicke BJ, Stephens AW, Gould T, et al. Tumor targeting by an aptamer. J Nucl Med. 2006;47:668–678
  205. Lappin G, Garner RC. Big physics, small doses: The use of AMS and PET in human microdosing of development drugs. Nat Rev Drug Discov. 2003;2:233–240
  206. Kummar S, Kinders R, Rubinstein L, et al. Compressing drug development timelines in oncology using phase ’0′ trials. Nat Rev Cancer. 2007;7:131–139

 This work was supported by Grant CA92871 to M.G.P.

PII: S1053-4296(07)00100-2

doi: 10.1016/j.semradonc.2007.10.009

Seminars in Radiation Oncology
Volume 18, Issue 2 , Pages 136-148 , April 2008

Article Tools

* Image Usage & Resolution